DA-001 / DA-002 / DA-005
Topical alpha-1 agonists — a family of related formulations betting on scalp blood flow rather than hormones.
- Developed by
- Applied Biology
- Current phase
- Phase 3
- Indications
- Androgenetic alopecia, Chemotherapy-induced alopecia, Telogen effluvium
- Also known as
- DA-001, DA-002, DA-005, DA-007, DA-020, topical phenylephrine
- Last public activity
- April 2026
- Record confidence
- Medium
Large confirmatory trials. The last step before filing.
How it is meant to work
Phenylephrine and related alpha-1 agonists constrict scalp vessels. In chemotherapy-induced hair loss the intent is to reduce how much cytotoxic drug reaches the follicle — the same principle as a cooling cap, attempted pharmacologically. The sponsor also describes a TAAR-agonist component in the shedding formulation. How this would work in androgenetic alopecia is not established by the registry records.
Why it matters
It is the clearest example in the register of one sponsor running a family of numbered formulations across several indications at once — shedding, pattern loss, and chemotherapy-induced alopecia. Filed as one row deliberately: the codes differ, the mechanism does not, and splitting them would suggest more independent programmes than exist.
Development history
- Phase 3
First Phase 3 trial on record: NCT06501924 — Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth
Applied Biology, Inc. · n=1120 · May 2026
Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia
Applied Biology, Inc. · n=60 · April 2026
Pharmacokinetic Study of DA-020
Applied Biology, Inc. · n=60 · April 2026
Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia
Applied Biology, Inc. · n=140 · October 2025
Pharmacokinetic Study of Topical Phenylephrine
Applied Biology, Inc. · n=24 · June 2025
Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
Applied Biology, Inc. · n=516 · January 2025
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss — ClinicalTrials.gov
- Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia — ClinicalTrials.gov
- Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth — ClinicalTrials.gov